1553TiP A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma

Annals of Oncology ◽

10.1016/j.annonc.2021.08.883 ◽

2021 ◽

Vol 32 ◽

pp. S1127

Author(s):

C. Schliemann ◽

D. Pink ◽

A. Flörcken ◽

M. Ahrens ◽

G. Egerer ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Tumor Targeting ◽

Phase Iii ◽

Human Antibody ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Metastatic Soft Tissue Sarcoma

Download Full-text

First-Line Therapy for Metastatic Soft Tissue Sarcoma

Current Treatment Options in Oncology ◽

10.1007/s11864-019-0606-9 ◽

2019 ◽

Vol 20 (1) ◽

Cited By ~ 10

Author(s):

Megan Meyer ◽

Mahesh Seetharam

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Metastatic Soft Tissue Sarcoma

Download Full-text

6519 ORAL Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71347-2 ◽

2007 ◽

Vol 5 (4) ◽

pp. 363 ◽

Cited By ~ 2

Author(s):

G. Scagliotti ◽

K. Park ◽

S. Patil ◽

J. Rolski ◽

T. Gorksel ◽

...

Keyword(s):

Lung Cancer ◽

Risk Profile ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Large Phase

Download Full-text

A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01)

Annals of Oncology ◽

10.1093/annonc/mdy282.064 ◽

2018 ◽

Vol 29 ◽

pp. viii228-viii229

Author(s):

K.-W. Lee ◽

C.H. Maeng ◽

T.-Y. Kim ◽

D.Y. Zang ◽

Y.H. Kim ◽

...

Keyword(s):

Gastric Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Recurrent Gastric Cancer ◽

Phase Iii Study

Download Full-text

Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps108 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS108-TPS108 ◽

Cited By ~ 3

Author(s):

W. Parulekar ◽

J. W. Chapman ◽

S. Aparicio ◽

Y. Murray ◽

F. M. Boyle ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Taxane Chemotherapy

Download Full-text

A randomized, multicenter phase III study of lobaplatin/etoposide versus cisplatin/etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating tumor cells (CTCs) as an exploratory biomarker.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.7595 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 7595-7595 ◽

Cited By ~ 2

Author(s):

Ying Cheng ◽

Yun Fan ◽

Xiaoqing Liu ◽

Yunpeng Liu ◽

Jiwei Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

Line Therapy ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

101 STRIDE: phase III study of therapeutic cancer vaccine L-BLP25 with hormonal treatment as first-line therapy for women with hormone receptor-positive, inoperable, locally advanced, recurrent, or metastatic breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)70132-4 ◽

2010 ◽

Vol 8 (3) ◽

pp. 87-88

Author(s):

W. Eiermann ◽

D. Miles ◽

T. Gilewski ◽

M. Trudeau ◽

B. Xu ◽

...

Keyword(s):

Locally Advanced ◽

Metastatic Breast ◽

Hormonal Treatment ◽

Phase Iii ◽

First Line ◽

Therapeutic Cancer Vaccine ◽

First Line Therapy ◽

Hormone Receptor Positive ◽

Line Therapy ◽

Phase Iii Study

Download Full-text

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.lba1011 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. LBA1011-LBA1011 ◽

Cited By ~ 87

Author(s):

D. Miles ◽

A. Chan ◽

G. Romieu ◽

L. Y. Dirix ◽

J. Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Locally Recurrent

Download Full-text

Sequential treatment strategy for metastatic colorectal cancer: A phase III study of chemotherapy (CT) with or without bevacizumab (Bev) as first-line therapy followed by two phase III studies of CT alone or CT plus bev with or without cetuximab (Cetux) as second-line therapy (ITACa Study IRST 153 01).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e14161 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e14161-e14161 ◽

Cited By ~ 1

Author(s):

F. Fabbri ◽

A. Passardi ◽

A. Ravaioli ◽

L. Cavanna ◽

G. Luppi ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Second Line ◽

First Line ◽

Second Line Therapy ◽

Two Phase ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Phase Iii Studies

Download Full-text

Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.102 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 102-102 ◽

Cited By ~ 2

Author(s):

Georgina V. Long ◽

Daniil Stroyakovskiy ◽

Helen Gogas ◽

Evgeny Levchenko ◽

Filippo G. De Braud ◽

...

Keyword(s):

Overall Survival ◽

Cutaneous Melanoma ◽

Braf V600e ◽

Phase Iii ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Double Blinded

Download Full-text

Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study

10.1183/13993003.congress-2021.oa4324 ◽

2021 ◽

Author(s):

Rolof G.P. Gijtenbeek ◽

V. Van Noort ◽

J.G.J.V. Aerts ◽

J.A. Staal - Van Den Brekel ◽

E.F. Smit ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Egfr Mutated

Download Full-text